InvestorsHub Logo
Post# of 26891
Next 10
Followers 437
Posts 42954
Boards Moderated 2
Alias Born 05/08/2006

Re: None

Tuesday, 09/19/2017 10:11:02 AM

Tuesday, September 19, 2017 10:11:02 AM

Post# of 26891
Compensated Awareness Post View Disclaimer
QualityStocksNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Retains Consulting Services of Ben Paterson

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced that it has retained the consulting services of Ben Paterson, P.E., to assist in defining the pathway for scale-up, purification and manufacturing strategies related to the company’s cannabinoid biosynthesis program. Paterson brings nearly four decades of experience in developing pharmaceutical manufacturing and purification processes to the InMed team, having previously served as a senior engineering advisor with Pharmaceutical giant Eli Lilly and Company for nearly four decades. “Mr. Paterson brings significant experience in all facets of biosynthesis manufacturing and facility design,” Eric A. Adams, president and CEO of InMed, stated in the news release. “His expertise directing complex capital projects, overseeing facilities and equipment, and interfacing with various stakeholders will be a significant asset to InMed.”

To view the full press release, visit http://dtn.fm/XJ9be

About InMed

InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.